Mobile

A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-000576-26

A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON-HODGKIN’S LYMPHOMA

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of GDC-0199 plus Bendamustine and Rituximab (BR) compared with BR alone in patients with R/R FL. To evaluate the efficacy of GDC-0199 plus rituximab in patients with Relapsed and Refractory Follicular non-hodgkins Lymphoma (R/R FL)

Critère d'inclusion

  • Relapsed and refractory follicular non-Hodgkins Lymphoma (R/R FL)

Liens